Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors

European Journal of Pharmacology

Volumn 341, Issue 1, 1998, Pages 39-44

  Gessa, Gianluigi ^a   Melis, Miriam ^a   Muntoni, Annalisa ^a   Diana, Marco ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cannabinoid; Dopamine; Drug abuse; Electrophysiology; Ventral tegmental area

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID RECEPTOR; DRONABINOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG COMPARISON; DRUG TOXICITY; ELECTROPHYSIOLOGY; INTRAVENOUS ADMINISTRATION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANESTHETICS; ANIMALS; CANNABINOIDS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIMBIC SYSTEM; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0032472382     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01442-8     Document Type: Article

References (33)

1. 2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res. 691:1995;106-114.
2. Castañeda E., Moss D.E., Oddie S.D., Whishaw I.Q. THC does not affect striatal dopamine release: Microdialysis in freely moving rats. Pharmacol. Biochem. Behav. 40(3):1991;587-591.
3. D'ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M., Beglin N.C., Chippari S.M., Grego J.D., Kullnig R.K., Daley G.T. Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem. 35:1992;124-135.
4. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
5. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
6. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38(2):1986;151-178.
7. Diana M., Garcia-Munoz M., Richards J., Freed C.R. Electrophysiological analysis of dopamine cells from the substantia nigra pars compacta of circling rats. Exp. Brain Res. 74:1989;625-630.
8. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Nat. Acad. Sci. 94:1988;5274-5278.
9. Einhorn L.C., Johansen P.A., White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: Studies in the ventral tegmental area. J. Neurosci. 8:1988;100-112.
10. 1 but not opioid receptors. Neurosci. Lett. 226:1997;159-162.
11. French E.D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. NeuroReport. 8:1997;649-652.
12. Gardner E.L., Lowinson J.H. Marijuana's interaction with brain reward systems: Update 1991. Pharmacol. Biochem. Behav. 40(3):1991;571-580.
13. 9-tetrahydrocannabinol. Psychopharmacology. 96:1988;142-144.
14. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
15. 9 dopamine neuronal activity in the rat. NeuroReport. 6:1995;207-209.
16. Herkenham M., Lynn A.B., De Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat brain. Brain Res. 547:1994;267-274.
17. Johnson, M.R., Melvin, L.S., 1986. The discovery of non classical cannabinoid analgetics. In: Cannabinoids as Therapeutic Agents. CRC Press, Boca Raton, pp. 121-145.
18. Kelland M.D., Freeman A.S., Chiodo L.A. Chloral hydrate anesthesia alters the responsiveness of identified midbrain dopamine neurons to dopamine agonist administration. Synapse. 3:1989;30-37.
19. Kelland M.D., Chiodo L.A., Freeman A.S. Anesthetic influence on the basal activity and pharmacologically responsiveness of nigrostriatal dopamine neurons. Synapse. 6:1990;207-209.
20. Lipsky J. Antidromic activation of neurones as an analytic tool in the study of the central nervous system. J. Neurosci. Methods. 4:1981;1-32.
21. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
22. Matthews R.T., German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience. 11:1984;617-625.
23. Melis M., Muntoni A.L., Diana M., Gessa G.L. The cannabinoid receptor agonist WIN 55,212-2 potently stimulates dopaminergic neuronal activity in the mesolimbic system. Behav. Pharmacol. 7 (Suppl. 1):1996;68.
24. Mereu G., Fadda F., Gessa G.L. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Res. 292:1984;63-69.
25. Mereu, G., Fanni, B., Gessa, G.L., 1984. General anesthetics prevent dopaminergic neuron stimulation by neuroleptics. In: Usdin, E., Carlsson, A., Dahlström, A., Engel, J. (Eds.), Cathecolamines, Part B: Neuropharmacology and Central Nervous System - Theoretical Aspects. Alan R. Liss, Inc., New York, pp. 353-358.
26. Mereu G., Kong-Woo P.Y., Boi V., Gessa G.L., Naes L., Westfall T.C. Preferential stimulation of ventral tegmental dopaminergic neurons by nicotine. Eur. J. Pharmacol. 141:1987;395-399.
27. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
28. 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: An in vivo electrochemical and in vivo microdialysis study. Brain Res. 451:1988;59-68.
29. Pertwee L.A., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56:1995;1949-1955.
30. Poddar M.K., Dewey W.L. Effect of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 214:1980;63-67.
31. Rinaldi-Carmona M., Barth F., Hèaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Nèliat G., Caput D., Ferrara P., Soubriè P., Brelièr J.C., Le Fur G. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
32. 9-Tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol. Biochem. Behav. 33(2):1989;397-400.
33. Sañudo-Peña M.C., Patrick S.L., Patrick R.L., Walker J.M. Effects of intranigral cannabinoids on rotational behaviour in rats: Interactions with the dopaminergic system. Neurosci. Lett. 206:1996;21-24.